Log in

NASDAQ:ALNAAllena Pharmaceuticals Stock Price, Forecast & News

$2.12
-0.20 (-8.62 %)
(As of 06/5/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.08
Now: $2.12
$2.36
50-Day Range
$1.18
MA: $1.78
$2.71
52-Week Range
$0.52
Now: $2.12
$6.30
Volume1.39 million shs
Average Volume964,237 shs
Market Capitalization$52.45 million
P/E RatioN/A
Dividend YieldN/A
Beta2.9
Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It also develops ALLN-346 for patients with hyperuricemia and moderate to severe chronic kidney diseases. The company was founded in 2011 and is headquartered in Newton, Massachusetts.
Read More
Allena Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.73 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ALNA
CUSIPN/A
Phone617-467-4577

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.73 per share

Profitability

Net Income$-47,340,000.00

Miscellaneous

Employees34
Market Cap$52.45 million
Next Earnings Date8/5/2020 (Estimated)
OptionableNot Optionable

Receive ALNA News and Ratings via Email

Sign-up to receive the latest news and ratings for ALNA and its competitors with MarketBeat's FREE daily newsletter.

Allena Pharmaceuticals (NASDAQ:ALNA) Frequently Asked Questions

How has Allena Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Allena Pharmaceuticals' stock was trading at $1.26 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ALNA shares have increased by 68.3% and is now trading at $2.12. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Allena Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allena Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Allena Pharmaceuticals.

When is Allena Pharmaceuticals' next earnings date?

Allena Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Allena Pharmaceuticals.

How were Allena Pharmaceuticals' earnings last quarter?

Allena Pharmaceuticals Inc (NASDAQ:ALNA) released its quarterly earnings data on Wednesday, May, 13th. The company reported ($0.31) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.45) by $0.14. View Allena Pharmaceuticals' earnings history.

What price target have analysts set for ALNA?

5 Wall Street analysts have issued 1 year target prices for Allena Pharmaceuticals' shares. Their forecasts range from $4.00 to $26.00. On average, they anticipate Allena Pharmaceuticals' share price to reach $11.60 in the next twelve months. This suggests a possible upside of 447.2% from the stock's current price. View analysts' price targets for Allena Pharmaceuticals.

Has Allena Pharmaceuticals been receiving favorable news coverage?

Media stories about ALNA stock have trended positive this week, according to InfoTrie Sentiment. The research group identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Allena Pharmaceuticals earned a daily sentiment score of 2.4 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news aboutAllena Pharmaceuticals.

Are investors shorting Allena Pharmaceuticals?

Allena Pharmaceuticals saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 321,400 shares, an increase of 11.1% from the April 30th total of 289,200 shares. Based on an average trading volume of 325,800 shares, the short-interest ratio is presently 1.0 days. Currently, 2.3% of the shares of the stock are short sold. View Allena Pharmaceuticals' Current Options Chain.

Who are some of Allena Pharmaceuticals' key competitors?

What other stocks do shareholders of Allena Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allena Pharmaceuticals investors own include Viking Therapeutics (VKTX), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Anavex Life Sciences (AVXL), Crispr Therapeutics (CRSP), Exelixis (EXEL), Matinas BioPharma (MTNB), Opko Health (OPK), Amarin (AMRN) and Pieris Pharmaceuticals (PIRS).

Who are Allena Pharmaceuticals' key executives?

Allena Pharmaceuticals' management team includes the following people:
  • Dr. Alexey L. Margolin, Co-Founder & Chairman (Age 67, Pay $427.95k)
  • Dr. Louis Brenner, Pres, CEO & Director (Age 50, Pay $507.28k)
  • Mr. Edward J. Wholihan, Chief Financial Officer (Age 60, Pay $387.03k)
  • Mr. Robert Gallotto, Co-Founder & Strategic Adviser (Age 55)
  • Mr. Hugh Wight, Sr. VP of Technical Operations

When did Allena Pharmaceuticals IPO?

(ALNA) raised $80 million in an initial public offering (IPO) on Thursday, November 2nd 2017. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. Credit Suisse, Jefferies and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Allena Pharmaceuticals' stock symbol?

Allena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNA."

Who are Allena Pharmaceuticals' major shareholders?

Allena Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Morgan Stanley (5.07%), Sphera Funds Management LTD. (2.70%) and BlackRock Inc. (0.49%). View institutional ownership trends for Allena Pharmaceuticals.

Which major investors are selling Allena Pharmaceuticals stock?

ALNA stock was sold by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., and BlackRock Inc.. View insider buying and selling activity for Allena Pharmaceuticals.

Which major investors are buying Allena Pharmaceuticals stock?

ALNA stock was purchased by a variety of institutional investors in the last quarter, including Morgan Stanley. View insider buying and selling activity for Allena Pharmaceuticals.

How do I buy shares of Allena Pharmaceuticals?

Shares of ALNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Allena Pharmaceuticals' stock price today?

One share of ALNA stock can currently be purchased for approximately $2.12.

How big of a company is Allena Pharmaceuticals?

Allena Pharmaceuticals has a market capitalization of $52.45 million. The company earns $-47,340,000.00 in net income (profit) each year or ($2.10) on an earnings per share basis. Allena Pharmaceuticals employs 34 workers across the globe.

What is Allena Pharmaceuticals' official website?

The official website for Allena Pharmaceuticals is www.allenapharma.com.

How can I contact Allena Pharmaceuticals?

Allena Pharmaceuticals' mailing address is ONE NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA, 02462. The company can be reached via phone at 617-467-4577.

This page was last updated on 6/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.